MedTrace Logo

Comparison of Different Insulin Dosing Algorithms Using Hepatic Directed Vesicle-Insulin Lispro and Insulin Degludec

NCT03938740 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2020-04-02

No results posted yet for this study

Summary

Multi-center, open-label, multiple dose safety, tolerability and efficacy study

Conditions

  • Diabetes Mellitus, Type 1

Interventions

DRUG

HDV-Insulin Lispro and Insulin Degludec (-40%)

HDV-Insulin Lispro and Insulin Degludec (-40%)

DRUG

HDV-Insulin Lispro and Insulin Degludec (-10%)

HDV-Insulin Lispro and Insulin Degludec (-10%)

Sponsors & Collaborators

  • Diasome Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Marc Penn, MD, PhD · Diasome Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-18
Primary Completion
2019-12-06
Completion
2020-03-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03938740 on ClinicalTrials.gov